The in vitro activity of ACHN-490, a novel aminoglycoside ("neoglycoside"), was evaluated against 102 multidrug-resistant (MDR) Klebsiella pneumoniae strains, including a subset of 25 strains producing the KPC carbapenemase. MIC 50 values for gentamicin, tobramycin, and amikacin were 8 g/ml, 32 g/ml, and 2 g/ml, respectively; MIC 90 values for the same antimicrobials were >64 g/ml, >64 g/ml, and 32 g/ml, respectively. ACHN-490 showed an MIC 50 of 0.5 g/ml and an MIC 90 of 1 g/ml, which are significantly lower than those of comparator aminoglycosides. ACHN-490 represents a promising aminoglycoside for the treatment of MDR K. pneumoniae isolates, including those producing KPC ␤-lactamase.
The spread of Klebsiella pneumoniae isolates producing extended-spectrum ␤-lactamases (ESBLs) represents a serious threat to our therapeutic armamentarium (21) . These isolates are also frequently resistant to other classes of antibiotics, such as ␤-lactam/ ␤-lactamase inhibitor combinations, quinolones, and aminoglycosides (8, 9) , thereby limiting our choice to carbapenems for the treatment of serious infections (21) .
Unfortunately, there is growing concern regarding the emergence of carbapenem-resistant K. pneumoniae isolates (20) . In particular, K. pneumoniae isolates producing KPC carbapenemases (KPC-Kp) are spreading at an alarming rate in North and South America, the Caribbean, Europe, Israel, and Asia (6, 7, 15, 17, 18) . Like ESBL producers, KPC-Kp are often resistant to quinolones and aminoglycosides (6) . Therefore, our therapeutic options against KPC-Kp are limited to tigecycline and colistin. However, tigecycline may not reach desired serum levels to treat bloodstream infections (19) , leaving colistin as the "last choice" against infections caused by KPC-Kp (13) . Unfortunately, colistin-resistant KPC-Kp isolates are also reported in the United States (1, 12) . As a result of this therapeutic dilemma, new antimicrobial agents with potent activity against multidrug-resistant (MDR) K. pneumoniae need to be developed.
Recently, there has been an increased interest in developing novel aminoglycosides. This new attention is due to (i) the potent bactericidal activity of aminoglycosides against a wide spectrum of aerobic gram-positive and gram-negative pathogens, (ii) the more gradual decline in susceptibility to aminoglycosides among gram-negative bacteria than that in susceptibility to other antimicrobials, and (iii) the ability of novel aminoglycosides to bypass common mechanisms of resistance that have gradually decreased the susceptibility to clinically used aminoglycosides (e.g., gentamicin, tobramycin, and amikacin) (11, 14, 16) .
ACHN-490 (Achaogen, San Francisco, CA) is a "neoglycoside," a next-generation aminoglycoside, currently in early clinical development (FDA, http://clinicaltrials.gov/), which has never been reported previously in the literature. The chemical structure of ACHN-490 is presented in Fig. 1 .
In the present work, we analyzed the in vitro activity of ACHN-490 against a collection of 102 K. pneumoniae clinical isolates collected from January 2006 to October 2007 at the University of Pittsburgh Medical Center, and three Cleveland institutions, including University Hospitals Case Medical Center, the Cleveland Clinic, and the Louis Stokes Department of Veterans Affairs Medical Center.
The 102 K. pneumoniae isolates were selected based on an MDR phenotype (i.e., resistance to Ն3 antibiotic classes). Twenty-five isolates were KPC-Kp and were part of a previous study in which the ␤-lactamase background and clonality were characterized (6) . The remaining 77 MDR K. pneumoniae isolates were ESBL producers, according to the phenotypic results (see below).
MICs were determined by a microdilution method using cation-adjusted Mueller-Hinton broth, according to the Clinical and Laboratory Standards Institute (CLSI) criteria (2) . Specific panels containing the following antibiotics were customized by Trek Diagnostics (Cleveland, OH): cefotaxime, cefotaxime-clavulanate (constant concentration of 4 mg/liter), ceftazidime, ceftazidime-clavulanate (constant concentration of 4 mg/liter), piperacillin-tazobactam, imipenem, ciprofloxacin, tigecycline, gentamicin, tobramycin, amikacin, arbekacin, neomycin, and ACHN-490. The following ATCC control strains were used: Escherichia coli 25922, Pseudomonas aeruginosa 27853, and K. pneumoniae 700603. Susceptibility results were interpreted according to the guidelines recommended by CLSI (3). Tigecycline MICs were interpreted according to the U.S. FDA criteria (i.e., susceptible at an MIC of Յ2 g/ml). According to the CLSI criteria, isolates were defined as ESBL producers when they showed a Ն3 twofold concentration decrease in MICs for ceftazidime or cefotaxime when tested in combination with clavulanate versus their MICs when tested alone (3).
The 25 KPC-Kp isolates were analyzed by PCR for the presence of 16S rRNA methylase genes (i.e., armA, rmtA, rmtB, rmtC, rmtD, and npmA), using primers and conditions previously reported (4, 23) . In addition, these strains were examined by PCR and sequencing for the presence of the most common aminoglycoside-modifying enzymes (AMEs) in gram-negative pathogens (22) . In particular, the following genes were analyzed:
3Ј)-VIa, and aph(3Ј)-VIb, using primers previously reported (5, 10).
As shown in Table 1 , MDR K. pneumoniae isolates were highly resistant to ceftazidime and piperacillin-tazobactam (each MIC 90 , Ͼ32 g/ml). Two-thirds of the isolates were resistant to ciprofloxacin, whereas approximately 75% and 90% of strains were still susceptible to imipenem and tigecycline, respectively. Almost all KPC-Kp isolates were resistant to ␤-lactams and quinolones, whereas tigecycline frequently remained active in vitro ( Table 1 ). All of these 25 isolates were colistin susceptible, as previously reported (6) . Figure 2 shows our analysis of aminoglycoside susceptibility. MDR K. pneumoniae isolates were highly resistant to gentamicin and tobramycin (less than 26% of strains were susceptible). In contrast, amikacin still maintained in vitro activity (78% of isolates were susceptible) with only five isolates being fully resistant (i.e., MICs of 64 g/ml). The subgroup of KPC-Kp showed lower susceptibility rates for amikacin and tobramycin (48% and 8%, respectively) than did the entire group of MDR strains (Fig. 2) . Notably, gentamicin was more active in vitro against KPC-Kp (44% of strains susceptible) than against the overall MDR isolate group.
For both MDR and KPC-Kp strains, ACHN-490 showed MIC 50 and MIC 90 values (i.e., 0.5 and 1 g/ml, respectively) that were significantly lower than those for comparator aminoglycosides. The ACHN-490 MICs for all strains were Յ4 g/ ml. In particular, the MIC 90 of ACHN-490 was at least 5 twofold dilutions lower than that of amikacin, which is currently the aminoglycoside with the least resistance in our armamentarium (Fig. 2) .
To better understand the impact of these susceptibility data, we investigated the genetic background of KPC-Kp isolates in terms of their AMEs and methylases. All KPC-Kp strains were positive for aac(6Ј)-Ib and ant(3Љ)-Ia (alternative name of aadA1) AME genes. Since neither of these AMEs modifies gentamicin, this explains the lower level of gentamicin resistance observed in the KPC-Kp strains. In contrast, the AAC(3)-II enzyme is common among Enterobacteriaceae and may be generating gentamicin resistance among the non-KPC-positive isolates (16) . Two KPC-Kp strains (i.e., VA362 and VA373) were also positive for the ant(2Љ)-Ia gene. Consistent with our MIC results (i.e., all strains with arbekacin MICs of Ͻ32 g/ml) and the low prevalence in the clinical population, we did not find any methylase genes. An E. coli control strain in which the rmtA methylase gene was cloned had an MIC of Ͼ8 g/ml for ACHN-490.
In conclusion, ACHN-490 possesses potent in vitro activity against MDR K. pneumoniae isolates, including those producing KPC carbapenemase. ACHN-490 represents a promising alternative to tigecycline and colistin for the treatment of isolates resistant to quinolones, ␤-lactam/␤- (3): ceftazidime (MIC, Յ8 g/ml); imipenem (MIC, Յ4 g/ml); piperacillin-tazobactam (MIC, Յ16 g/ml); ciprofloxacin (MIC, Յ1 g/ml); amikacin (MIC, Յ16 g/ml); gentamicin (MIC, Յ4 g/ml); tobramycin (MIC, Յ4 g/ml).
b Tigecycline was interpreted according to U.S. FDA criteria (susceptibility, MIC Յ 2 g/ml).
c CLSI criteria not available. lactamase inhibitor combinations, carbapenems, and existing aminoglycosides.
